Could a cancer pill shrink kaposi tumors?

NCT ID NCT04305691

Recruiting now Disease control Sponsor: AIDS Malignancy Consortium Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called ixazomib in people with Kaposi sarcoma, a type of skin cancer. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors and will monitor side effects. About 41 adults with measurable skin lesions are being recruited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Kaposi's sarcoma skin neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KAPOSI SARCOMA SKIN

Contacts and locations

Locations

Abramson Cancer Center at Pennsylvania Hospital
RECRUITING

Philadelphia, Pennsylvania, 19106, United States
Mount Sinai Hospital
RECRUITING

New York, New York, 10029, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITING

Baltimore, Maryland, 21287, United States
Thomas Street Clinic
RECRUITING

Houston, Texas, 77004, United States
Thomas Street Clinic
RECRUITING

Houston, Texas, 77004, United States
UC San Diego
RECRUITING

San Diego, California, 92093, United States
University of Illinois Cancer Center
RECRUITING

Chicago, Illinois, 60612, United States
University of Miami Miller School of Medicine
RECRUITING

Miami, Florida, 33136, United States
Virginia Mason Medical Center
RECRUITING

Seattle, Washington, 98101, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States
Zuckerberg San Francisco General Hospital
RECRUITING

San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.